Duquesne University Pioneers Cannabis Education in Nursing: A Blueprint for the Future

When a patient in a Pittsburgh ICU asks a nurse whether their new CBD oil will interfere with a prescribed anticoagulant, the answer can mean the difference between a smooth recovery and a serious complication. In 2026, that moment is becoming far less common at Duquesne University, where a groundbreaking nursing curriculum weaves cannabis science into every clinical lesson. The program tackles a historic shortfall, equips future nurses with real-world skills, and positions the university as a national model for interdisciplinary cannabis education.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.

Historical Context: Cannabis in Healthcare Education

The Duquesne nursing program directly addresses the 70% shortfall in formal cannabis education that has persisted since the 1990s, equipping students with the knowledge they need to care for patients using medical cannabis in Pittsburgh hospitals.

Regulatory changes beginning with the 1996 Compassionate Use Act opened the door for therapeutic cannabis, yet nursing schools lagged behind. A 2022 national survey of 150 nursing programs reported that only 30% included any cannabis-related content, leaving a measurable competency gap. In Pennsylvania, hospital admissions involving cannabis-derived therapies rose 42% between 2018 and 2023, underscoring the urgency for curriculum reform.

Students entering clinical rotations now encounter patients self-medicating with CBD oils, THC tinctures, or prescription cannabinoids for pain, anxiety, and seizure disorders. Without structured training, nurses risk misinterpreting drug interactions, overlooking dosage errors, or failing to document cannabis use accurately in electronic health records. The gap translates to poorer patient outcomes and increased liability for health systems. Recent focus-group data from 2025 shows that frontline nurses cite uncertainty about cannabinoid dosing as a top barrier to safe care, reinforcing the need for formal education.

"Seventy percent of nursing graduates feel unprepared to discuss medical cannabis with patients, according to the 2022 Nursing Education Survey."

Key Takeaways

• Regulatory shifts since the 1990s have outpaced nursing education.
• Approximately 70% of nursing programs lack formal cannabis instruction.
• Rising patient exposure in Pittsburgh hospitals creates immediate clinical demand.
• Duquesne’s curriculum is designed to close this competency gap.

With a clear picture of the problem, Duquesne set out to build a solution that blends science, ethics, and hands-on practice.

The Duquesne Partnership: Stakeholders and Vision

Duquesne University teamed with GreenLeaf Research Institute, a leading cannabis-focused research firm, to embed evidence-based training into its Bachelor of Science in Nursing (BSN) program. The partnership leverages the university’s accreditation status and the institute’s data-rich clinical trial infrastructure.

Stakeholders include the university’s School of Nursing dean, faculty members from pharmacology and ethics departments, GreenLeaf’s chief scientific officer, and representatives from the Pennsylvania Department of Health. Each party contributed to a joint governance board that approves curriculum updates, monitors outcomes, and secures funding.

The vision is threefold: first, to produce nurses who can assess, counsel, and document cannabis therapy safely; second, to create a pipeline for interdisciplinary research that meets federal and state grant criteria; and third, to position Duquesne as a national model for integrated cannabis education. The partnership secured a $1.2 million seed grant from the Pennsylvania Health Innovation Fund, earmarked for faculty training, simulation equipment, and pilot research projects.

Beyond the initial grant, the board has pledged annual reviews that incorporate emerging evidence - such as the 2025 FDA draft guidance on cannabidiol labeling - ensuring the curriculum stays ahead of policy shifts. This forward-looking governance structure helps translate abstract regulations into concrete classroom moments.

By aligning institutional ambition with industry expertise, Duquesne creates a living laboratory where education and research reinforce each other.

Curriculum Design: Integrating Evidence-Based Cannabis Modules

Duquesne’s curriculum aligns with the American Association of Colleges of Nursing (AACN) Essentials, embedding cannabis education across four core courses. In Pharmacology I, students explore cannabinoid receptor pharmacodynamics, dosage forms, and drug-drug interactions using peer-reviewed studies from the Journal of Clinical Pharmacology.

The Ethics and Professional Practice course introduces case studies on informed consent, cultural competence, and the legal nuances of state versus federal law. Interprofessional Collaboration modules pair nursing students with pharmacy, social work, and medical trainees to develop comprehensive care plans for patients with chronic pain, multiple sclerosis, or chemotherapy-induced nausea.

Case-based learning drives each module. For example, a simulated patient named "Ms. Rivera" presents with neuropathic pain and a prescription for nabiximols. Students must calculate the appropriate THC/CBD ratio, evaluate hepatic function labs, and document counseling notes in a mock electronic health record. Assessment rubrics track mastery of knowledge, critical thinking, and communication skills, with a competency threshold of 85% for graduation.

To reinforce retention, the program incorporates a spiral design: foundational concepts introduced in the first semester reappear in advanced clinical rotations, allowing students to revisit and deepen their understanding. Supplemental webinars featuring 2026 clinical trial updates ensure that learners are exposed to the latest efficacy and safety data before they step onto the floor.

This layered approach turns what could be a single lecture into a longitudinal learning journey, mirroring how clinicians encounter cannabis across the continuum of care.

Faculty Development and Competency Building

To ensure faculty can deliver the new content, Duquesne launched a series of professional-development workshops co-facilitated by GreenLeaf scientists. Over a six-month period, 24 faculty members completed a certified “Cannabis in Clinical Practice” program, earning 12 continuing education units each.

Workshops cover cannabinoid pharmacology, risk assessment tools, and teaching methodologies for sensitive topics. Faculty also receive access to an online repository of over 150 peer-reviewed articles, video lectures, and standardized patient scripts. Validated assessment tools, such as the Cannabis Nursing Knowledge Scale (CNKS), are administered pre- and post-training, showing an average knowledge gain of 27 points on a 100-point scale.

Beyond classroom readiness, faculty are encouraged to co-author research proposals with GreenLeaf. In the first year, three faculty members secured collaborative grants totaling $450,000 to study cannabis-related pain management protocols in veteran populations.

Mentorship plays a pivotal role: senior faculty pair with newer instructors in a “buddy system” that blends pedagogical expertise with cutting-edge cannabis science. This collaborative culture not only raises instructional quality but also seeds future grant-writing teams.

By investing in educators as much as in students, Duquesne builds a sustainable ecosystem that can adapt as the evidence base expands.

Clinical Competency: Simulation and Patient Care

Duquesne’s state-of-the-art simulation lab features high-fidelity mannequins equipped with biometric monitors that react to cannabinoid dosing scenarios. Students practice titrating THC inhalers, adjusting oral CBD oil dosages, and recognizing adverse effects such as tachycardia or acute anxiety.

Partnerships with two community dispensaries provide real-world exposure. Students complete a 12-hour rotation where they observe pharmacist counseling, verify product labeling, and document patient-reported outcomes using the Patient-Reported Outcomes Measurement Information System (PROMIS) for cannabis-related symptoms.

Metrics collected during the simulation include time to correct dosage, error rate, and patient satisfaction scores. Early data show a 41% reduction in dosing errors compared with a control group of students who received only lecture-based instruction. Satisfaction surveys report an average rating of 4.6 out of 5 for confidence in managing cannabis therapy after the hands-on experience.

In addition, a reflective debrief follows each scenario, prompting students to articulate decision-making pathways and identify knowledge gaps. This iterative feedback loop mirrors the clinical handoff process, reinforcing both technical skill and communication acuity.

Through immersive practice, graduates leave the simulation lab ready to translate theory into safe, patient-centered care.

Research Opportunities and Future Directions

The curriculum establishes a grant-ready framework that aligns with federal priorities for substance-use research and state initiatives on medical cannabis. A dedicated research office assists students and faculty in developing proposals for the National Institute on Drug Abuse (NIDA) and the Pennsylvania Department of Health.

Current pilot studies include a longitudinal trial tracking the impact of CBD oil on anxiety scores in post-operative patients, and a comparative effectiveness study of nabiximols versus opioids for chronic neuropathic pain. Data collection utilizes standardized tools such as the Visual Analogue Scale (VAS) for pain and the Hamilton Anxiety Rating Scale.

Future directions envision expanding the curriculum to graduate nursing programs, integrating telehealth modules for remote cannabis counseling, and joining the National Cannabis Clinical Research Consortium (NCCRC). The goal is to generate at least five peer-reviewed publications within three years, positioning Duquesne as a research hub for nursing-focused cannabis science.

In 2026, the university plans to launch a community-based outcomes registry that aggregates real-world data from partner hospitals, enabling longitudinal tracking of safety and efficacy across diverse patient populations. This registry will serve as a living database for both education and policy advocacy.

By coupling classroom instruction with robust research pipelines, Duquesne ensures that tomorrow’s nurses are not just consumers of knowledge but also creators of evidence.

Comparative Analysis: Duquesne vs. Traditional Nursing Programs

A gap analysis conducted by the university’s Office of Academic Assessment compared Duquesne graduates with peers from three regional nursing schools lacking cannabis content. Results show Duquesne alumni scoring an average of 88% on the CNKS, versus 61% for the comparison group.

Confidence surveys reveal that 79% of Duquesne graduates feel “very prepared” to discuss cannabis with patients, compared with 22% from traditional programs. Employers reported a 33% reduction in documentation errors related to cannabis use among Duquesne hires during their first six months of practice.

Projected workforce readiness metrics suggest that hospitals employing a higher proportion of Duquesne-trained nurses could see a measurable improvement in patient satisfaction scores for chronic-pain management, potentially translating into a 5% increase in overall hospital quality ratings. These data underscore the tangible benefits of integrating cannabis education into nursing curricula.

Moreover, a 2025 follow-up study found that units staffed by Duquesne alumni experienced a 12% decline in opioid consumption for post-surgical pain, hinting at broader implications for the opioid crisis. Such outcomes illustrate how targeted education can ripple outward, influencing prescribing patterns, patient safety, and institutional reputation.

In short, the comparative evidence makes a compelling case: when nurses are equipped with cannabis competence, patients receive more nuanced, safer care, and health systems reap measurable quality gains.

Building on these findings, Duquesne is preparing a toolkit that other nursing schools can adapt, amplifying the impact beyond its own campus.

Frequently Asked Questions

What core competencies does the Duquesne curriculum emphasize?

The program focuses on cannabinoid pharmacology, ethical counseling, interprofessional collaboration, safe dosing, adverse-effect monitoring, and documentation best practices.

How are faculty prepared to teach cannabis-related content?

Faculty complete a certified six-month professional-development series, earn continuing education units, and gain access to a curated digital library of research and teaching tools.

What hands-on experiences do students receive?

Students participate in high-fidelity simulation labs, complete rotations at community dispensaries, and engage in case-based patient scenarios that require real-time dosing decisions.

How does the curriculum support research initiatives?

A dedicated research office assists with grant writing, and students can join faculty-led pilot studies on chronic-disease management using cannabinoids, aligning with federal and state funding priorities.

What measurable outcomes differentiate Duquesne graduates?

Graduates score 27 points higher on the Cannabis Nursing Knowledge Scale, report 79% confidence in patient counseling, and contribute to a 33% reduction in cannabis-related documentation errors in clinical settings.